GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 33 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $31,337,695 | +107.2% | 10,881,144 | +174.1% | 3.43% | +228.8% |
Q2 2023 | $15,123,517 | +455.4% | 3,969,427 | +171.1% | 1.04% | +452.4% |
Q1 2023 | $2,723,008 | +123057.3% | 1,463,983 | +52.3% | 0.19% | -25.9% |
Q4 2022 | $2,211 | -99.9% | 961,358 | -0.0% | 0.26% | -25.4% |
Q3 2022 | $3,096,000 | -41.4% | 961,359 | 0.0% | 0.34% | -35.6% |
Q2 2022 | $5,287,000 | +136.0% | 961,359 | 0.0% | 0.53% | +244.8% |
Q1 2022 | $2,240,000 | -61.4% | 961,359 | 0.0% | 0.15% | -56.0% |
Q4 2021 | $5,807,000 | -56.4% | 961,359 | 0.0% | 0.35% | -41.6% |
Q3 2021 | $13,334,000 | -22.8% | 961,359 | -27.6% | 0.60% | -19.8% |
Q2 2021 | $17,267,000 | -26.4% | 1,328,257 | -12.8% | 0.75% | -9.3% |
Q1 2021 | $23,454,000 | – | 1,522,994 | – | 0.82% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
Capital International Sarl | 228,149 | $532,000 | 0.03% |
FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |